Asia
Life science and pharma companies strengthen their leadership teams with this week’s appointments.
ASLAN Pharmaceuticals announced the presentation of new data from a phase 1b open-label, dose escalation study of varlitinib in combination with modified irinotecan and infusional 5-fluorouracil chemotherapy to determine the safety, tolerability and maximum tolerated dose in advanced solid tumours.
Companies from across the globe share information on their business and pipelines.
TLC announced the initiation of a Phase III clinical trial (“EXCELLENCE”) to evaluate the efficacy and safety of single as well as repeated doses of TLC599 in patients with osteoarthritis (OA) of the knee.
Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China.
International precision medicine firm Lucence Diagnostics announced that it has received the Clinical Laboratory Improvement Amendments certification for its laboratory in Singapore from the U.S. Department of Health and Human Services’ Centers for Medicare & Medicaid Services.
Studies on a novel protein that helps cancer cells to grow and spread may help in the development of more efficient therapies for liver cancer
Eisai Co., Ltd. and Tokio Marine & Nichido Fire Insurance Co., Ltd. announced that the companies have entered into a business alliance agreement for co-existence and prevention of dementia.
Eisai Co., Ltd. and FRONTEO, Inc. announced that they have launched the tumbling and falling prediction system Coroban to medical institutions in Japan on September 26, 2019.
Biotech and pharma companies strengthen their leadership teams and boards of directors with this week’s appointments.
PRESS RELEASES